eBook - ePub
Heart Failure
An Essential Clinical Guide
Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler, Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler
This is a test
Condividi libro
- 392 pagine
- English
- ePUB (disponibile sull'app)
- Disponibile su iOS e Android
eBook - ePub
Heart Failure
An Essential Clinical Guide
Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler, Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler
Dettagli del libro
Anteprima del libro
Indice dei contenuti
Citazioni
Informazioni sul libro
This "patient-oriented" book was written as a meeting ground for practicing clinicians, allied health professionals, and clinical researchers to provide a practical guide for the contemporary assessment and management of patients with heart failure and cardiomyopathy. It revolves around broad patient scenarios to elegantly (or expertly) guide diagnostic and management strategies. Combining the talents of over one-hundred experts in the field, the book also endeavors to challenge the reader with areas of current controversies and opportunities for clinical investigation with the goals of both orienting clinicians and stimulating their research passions.
Key Features
-
- Provides practical guidance based on real-life heart failure scenarios
-
- Discusses both acute and chronic care patient-oriented scenarios
-
- Covers up-to-date and novel concepts in heart failure
-
- Features the perspectives of current debates and controversies in heart failure
-
- Highlights the opportunities for research in this field
Domande frequenti
Come faccio ad annullare l'abbonamento?
È semplicissimo: basta accedere alla sezione Account nelle Impostazioni e cliccare su "Annulla abbonamento". Dopo la cancellazione, l'abbonamento rimarrà attivo per il periodo rimanente già pagato. Per maggiori informazioni, clicca qui
È possibile scaricare libri? Se sì, come?
Al momento è possibile scaricare tramite l'app tutti i nostri libri ePub mobile-friendly. Anche la maggior parte dei nostri PDF è scaricabile e stiamo lavorando per rendere disponibile quanto prima il download di tutti gli altri file. Per maggiori informazioni, clicca qui
Che differenza c'è tra i piani?
Entrambi i piani ti danno accesso illimitato alla libreria e a tutte le funzionalità di Perlego. Le uniche differenze sono il prezzo e il periodo di abbonamento: con il piano annuale risparmierai circa il 30% rispetto a 12 rate con quello mensile.
Cos'è Perlego?
Perlego è un servizio di abbonamento a testi accademici, che ti permette di accedere a un'intera libreria online a un prezzo inferiore rispetto a quello che pagheresti per acquistare un singolo libro al mese. Con oltre 1 milione di testi suddivisi in più di 1.000 categorie, troverai sicuramente ciò che fa per te! Per maggiori informazioni, clicca qui.
Perlego supporta la sintesi vocale?
Cerca l'icona Sintesi vocale nel prossimo libro che leggerai per verificare se è possibile riprodurre l'audio. Questo strumento permette di leggere il testo a voce alta, evidenziandolo man mano che la lettura procede. Puoi aumentare o diminuire la velocità della sintesi vocale, oppure sospendere la riproduzione. Per maggiori informazioni, clicca qui.
Heart Failure è disponibile online in formato PDF/ePub?
Sì, puoi accedere a Heart Failure di Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler, Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler in formato PDF e/o ePub, così come ad altri libri molto apprezzati nelle sezioni relative a Medicine e Medical Theory, Practice & Reference. Scopri oltre 1 milione di libri disponibili nel nostro catalogo.
Informazioni
Section III
Managing Chronic Heart Failure
DOI: 10.1201/9780429244544-12
Chapter 10 Outpatient Management of Stable Heart Failure with Reduced Ejection Fraction
Chapter 11 Exercise and Rehabilitation in Heart Failure
Chapter 12 The Patient with Ischemic Heart Failure
Chapter 13 The Non-Ischemic HEART FAILURE Patient
Chapter 14 Valvular Heart Disease and Heart Failure
Chapter 15 The Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)
Chapter 16 Heart Failure with Recovered Ejection Fraction (HFrecEF) and Heart Failure with Midrange Ejection Fraction (HFmrEF)
Chapter 17 The Advanced HEART FAILURE Patient
Chapter 18 Palliative Care and Advanced Directives in Heart Failure
Chapter 10
OUTPATIENT MANAGEMENT OF STABLE HEART FAILURE WITH REDUCED EJECTION FRACTION
Leah Reid, Jonathan Murrow, Kent Nilsson, and Catherine Marti
DOI: 10.1201/9780429244544-13
Introduction
Although therapies for HF with preserved ejection fraction (HFpEF) are lacking, there are many therapies available to patients with HF with reduced ejection fraction (HFrEF), regardless of symptomatology.1 Careful consideration should be taken at every encounter to evaluate not only volume status but also to optimize guideline-directed medical therapy as well as device therapy. In this chapter, we outline the current therapy available for outpatient management of HFrEF (Table 10.1).
| Starting Dose (mg) | Target Dose (mg) |
Beta-Blockers | ||
Bisoprolol | 1.25 daily | 10 daily |
Carvedilol | 3.125 b.i.d. | 25 b.i.d. for weight <85 kg and 50 b.i.d. for weight ≥85 kg |
Metoprolol succinate | 12.5–25 daily | 200 daily |
Angiotensin Receptor Neprilysin Inhibitors | ||
Sacubitril/valsartan | 24/26–49/51 b.i.d. | 97/103 b.i.d. |
Angiotensin-Converting Enzyme Inhibitors | ||
Captopril | 6.25 t.i.d. | 50 t.i.d. |
Enalapril | 2.5 b.i.d. | 10–20 b.i.d. |
Lisinopril | 2.5–5.0 daily | 20–40 daily |
Ramipril | 1.25 daily | 10 daily |
Angiotensin II Receptor Blockers | ||
Candesartan | 4–8 daily | 32 daily |
Losartan | 25–50 daily | 150 daily |
Valsartan | 40 b.i.d. | 160 b.i.d. |
Aldosterone Antagonists | ||
Eplerenone | 25 daily | 50 daily |
Spironolactone | 12.5–25 daily | 25–50 daily |
Sodium-Glucose Cotransporter-2 Inhibitors | ||
Dapagliflozin | 10 daily | 10 daily |
Empagliflozin | 10 daily | 10 daily |
Vasodilators | ||
Hydralazine | 25 t.i.d. | 75 t.i.d. |
Isosorbide dinitrate | 20 t.i.d. | 40 t.i.d. |
Fixed-dose combination isosorbide dinitrate/hydralazine | 20/37.5 (1 tab) t.i.d. | 2 tabs t.i.d. |
Ivabradine | ||
Ivabradine | 2.5–5 b.i.d. | Titrate to heart rate 50–60 beats/min. Maximum dose 7.5 b.i.d. |
Notes: Isosorbide mononitrate is not recommended by current guidelines, which consider either the fixed-dose combination or the separate combination of isosorbide dinitrate and hydralazine as appropriate guideline-directed therapies for heart failure. | ||
Abbreviations: b.i.d. = bis in die (twice daily); t.i.d. = ter in die (three times daily). | ||
Source: Reproduced with permission from: Maddox et al., J Am Coll Cardiol 2021;77:772–810. |
Beta-Blockers
Maladaptive activation of the sympathetic nervous system in HFrEF can lead to worsening congestion, malperfusion, and arrhythmias.2 Blockade of β-adrenergic receptors has proven in multiple clinical trials to reduce morbidity and mortality—specifically with metoprolol succinate and bisoprolol, which selectively block β-1-receptors, and with carvedilol, which selectively blocks α-1, β-1 and β-2 receptors.3
In the landmark Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), patients with HFrEF (ejection fraction [EF] ≤35%) and New York Heart Association (NYHA) class II–IV symptoms had a 34% relative risk reduction in all-cause mortality with bisoprolol therapy vs placebo.4 The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) and carvedilol trials likewise demonstrated reduced risk of death or HF hospitalization (Figure 10.1).5–7 To reduce morbidity and mortality, the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Heart Failure Guidelines thus recommend using either bisoprolol, carvedilol, or sustained-release metoprolol succinate for all patients with current or prior symptoms of HFrEF unless contraindicated (class I, level of evidence [LOE]: A). Importantly, the benefit of β blockers is dose dependent, with lower achieved heart rates associated with improved outcomes, albeit this effect is mostly relevant to patients in sinus rhythm and not among those with atrial fibrillation.8 A network meta-analysis of 21 trials found a mortality benefit of β blockers vs p...